While Acadia Pharmaceuticals Inc. disappointed investors and analysts during a May 2 conference call by not disclosing the price of the firm's newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), the company insisted the medicine, nonetheless, is likely to be covered by the "vast majority" of payers.
Analysts, however, anticipated Acadia to reveal Nuplazid's price as soon as May 5, when the firm holds its quarterly earnings...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
